Stay updated on Tagraxofusp in Secondary AML Clinical Trial
Sign up to get notified when there's something new on the Tagraxofusp in Secondary AML Clinical Trial page.

Latest updates to the Tagraxofusp in Secondary AML Clinical Trial page
- Check5 days agoNo Change Detected
- Check12 days agoChange DetectedAdded Study Description and Study Status entries to the record history (dated 2025-12-17) with Revision: v3.3.3. Removed the HHS Vulnerability Disclosure footer link.SummaryDifference0.6%

- Check19 days agoChange DetectedThe record history now includes additions of core sections (Eligibility, Outcome Measures, Arms and Interventions, Study Description, Oversight, Study Status, Study Identification) and a title change from 'With or Without Venetoclax' to 'With Venetoclax' for the TAGALONG trial.SummaryDifference0.9%

- Check26 days agoNo Change Detected
- Check41 days agoChange DetectedThe page history shows a new UI revision entry (Revision: v3.3.2) and removal of Revision: v3.2.0. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check48 days agoChange DetectedThe government funding and operating status notice has been removed from the page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.6%

- Check62 days agoChange DetectedA new version entry has been added to the Record History with a newer submission date, updating the study status in the history table. This reflects the ongoing updates to the trial record on ClinicalTrials.gov.SummaryDifference0.1%

- Check91 days agoChange DetectedMajor change: page now carries a government-operating-status notice and a new version tag (v3.2.0) replacing the old one (v3.1.0).SummaryDifference12%

Stay in the know with updates to Tagraxofusp in Secondary AML Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Tagraxofusp in Secondary AML Clinical Trial page.